These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 14739157)

  • 1. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan.
    Tran PK; Tran-Lundmark K; Soininen R; Tryggvason K; Thyberg J; Hedin U
    Circ Res; 2004 Mar; 94(4):550-8. PubMed ID: 14739157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN.
    Garl PJ; Wenzlau JM; Walker HA; Whitelock JM; Costell M; Weiser-Evans MC
    Circ Res; 2004 Feb; 94(2):175-83. PubMed ID: 14656929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.
    Segev A; Nili N; Osherov AB; Qiang B; Wong AJ; Pillarisetti S; Strauss BH
    EuroIntervention; 2010 May; 6(1):134-40. PubMed ID: 20542809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury.
    Gotha L; Lim SY; Osherov AB; Wolff R; Qiang B; Erlich I; Nili N; Pillarisetti S; Chang YT; Tran PK; Tryggvason K; Hedin U; Tran-Lundmark K; Advani SL; Gilbert RE; Strauss BH
    Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H337-45. PubMed ID: 24858854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice.
    Zhou Z; Wang J; Cao R; Morita H; Soininen R; Chan KM; Liu B; Cao Y; Tryggvason K
    Cancer Res; 2004 Jul; 64(14):4699-702. PubMed ID: 15256433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion.
    Kinsella MG; Tran PK; Weiser-Evans MC; Reidy M; Majack RA; Wight TN
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):608-14. PubMed ID: 12615671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation.
    Francis DJ; Parish CR; McGarry M; Santiago FS; Lowe HC; Brown KJ; Bingley JA; Hayward IP; Cowden WB; Campbell JH; Campbell GR; Chesterman CN; Khachigian LM
    Circ Res; 2003 May; 92(8):e70-7. PubMed ID: 12690039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of perlecan in arterial injury and angiogenesis.
    Segev A; Nili N; Strauss BH
    Cardiovasc Res; 2004 Sep; 63(4):603-10. PubMed ID: 15306215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries.
    Kinsella MG; Irvin C; Reidy MA; Wight TN
    Atherosclerosis; 2004 Jul; 175(1):51-7. PubMed ID: 15186946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors.
    Smith SM; West LA; Govindraj P; Zhang X; Ornitz DM; Hassell JR
    Matrix Biol; 2007 Apr; 26(3):175-84. PubMed ID: 17169545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease.
    Snow AD; Kinsella MG; Parks E; Sekiguchi RT; Miller JD; Kimata K; Wight TN
    Arch Biochem Biophys; 1995 Jun; 320(1):84-95. PubMed ID: 7793988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perlecan Heparan Sulfate Is Required for the Inhibition of Smooth Muscle Cell Proliferation by All-trans-Retinoic Acid.
    Tran-Lundmark K; Tannenberg P; Rauch BH; Ekstrand J; Tran PK; Hedin U; Kinsella MG
    J Cell Physiol; 2015 Feb; 230(2):482-7. PubMed ID: 25078760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perlecan is responsible for thrombospondin 1 binding on the cell surface of cultured porcine endothelial cells.
    Vischer P; Feitsma K; Schön P; Völker W
    Eur J Cell Biol; 1997 Aug; 73(4):332-43. PubMed ID: 9270876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells.
    Dodge GR; Boesler EW; Jimenez SA
    Lab Invest; 1995 Nov; 73(5):649-57. PubMed ID: 7474938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia.
    Kuzuya M; Kanda S; Sasaki T; Tamaya-Mori N; Cheng XW; Itoh T; Itohara S; Iguchi A
    Circulation; 2003 Sep; 108(11):1375-81. PubMed ID: 12939223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells.
    Mathiak M; Yenisey C; Grant DS; Sharma B; Iozzo RV
    Cancer Res; 1997 Jun; 57(11):2130-6. PubMed ID: 9187109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laminarin sulfate mimics the effects of heparin on smooth muscle cell proliferation and basic fibroblast growth factor-receptor binding and mitogenic activity.
    Miao HQ; Ishai-Michaeli R; Peretz T; Vlodavsky I
    J Cell Physiol; 1995 Sep; 164(3):482-90. PubMed ID: 7650058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor-1alpha in a mouse model of carotid artery ligation.
    Zhang LN; Wilson DW; da Cunha V; Sullivan ME; Vergona R; Rutledge JC; Wang YX
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):765-72. PubMed ID: 16456092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury.
    Kobayashi K; Yokote K; Fujimoto M; Yamashita K; Sakamoto A; Kitahara M; Kawamura H; Maezawa Y; Asaumi S; Tokuhisa T; Mori S; Saito Y
    Circ Res; 2005 Apr; 96(8):904-12. PubMed ID: 15790953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.
    Gizard F; Amant C; Barbier O; Bellosta S; Robillard R; Percevault F; Sevestre H; Krimpenfort P; Corsini A; Rochette J; Glineur C; Fruchart JC; Torpier G; Staels B
    J Clin Invest; 2005 Nov; 115(11):3228-38. PubMed ID: 16239970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.